Biodesix Announces Third Quarter 2025 Results and Highlights
Biodesix, Inc. (BDSX)
Company Research
Source: GlobeNewswire
Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. “We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year,” said Scott Hutton, Chief Executive Officer. “Our strategic expansion into primary care is proving to be additive, demonstrating our ability to drive adoption in pulmonology while also partnering with them to drive upstream testing in their referral network. Additionally, our Development Services business continues to acceler
Show less
Read more
Impact Snapshot
Event Time:
BDSX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDSX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDSX alerts
High impacting Biodesix, Inc. news events
Weekly update
A roundup of the hottest topics
BDSX
News
- Biodesix (NASDAQ:BDSX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Biodesix to Present New Data at Two Major Upcoming Scientific MeetingsGlobeNewswire
- Biodesix (NASDAQ:BDSX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Biodesix (NASDAQ:BDSX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BDSX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
- Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual MeetingGlobeNewswire
BDSX
Earnings
- 11/3/25 - Beat
BDSX
Analyst Actions
- 9/19/25 - Canaccord Genuity
BDSX
Sec Filings
- 11/3/25 - Form 10-Q
- 11/3/25 - Form 8-K
- 10/2/25 - Form 4
- BDSX's page on the SEC website